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Abstract 
Introduction: Community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae is a substantial cause of morbidity 
and mortality among older adults. This study estimated incidences of CAP, chest x-ray−confirmed CAP (CXR+CAP), S pneumo-
niae-positive CAP, S pneumoniae-positive CXR+CAP, and S. pneumoniae serotype distribution among 46,000 at-risk adults aged 
≥ 50 years residing in Chrzanów County, Poland. 
Material and methods: From January 2010 to January 2012, all facilities providing ambulatory and inpatient care enrolled all 
consenting resident patients with suspicion of CAP. Chest x-rays, urine, blood, and sputum samples were analyzed. Annualized 
incidence rates were determined. Presence of S pneumoniae-positive CAP and/or S. pneumoniae serotype distribution was de-
termined using the urine antigen detection assay (capable of detecting the serotypes in the 13-valent pneumococcal conjugate 
vaccine [PCV13]), BinaxNOW®, and/or microbiology cultures.
Results: Among 5055 enrolled patients, 1195 (23.7%) were diagnosed with CAP and 1166 (23.4%) had CXR+CAP. S. pneumoniae was 
detected in 144 (12.1%) and 131 (11.2%) patients from the CAP and CXR+CAP cohorts, respectively. Annualized incidence rates of CAP, 
CXR+CAP, S pneumoniae-positive CAP, and S. pneumoniae-positive CXR+CAP were 12.8, 12.5, 1.6, and 1.4 per 1000 residents, respectively. 
Among CXR+CAP patients, 39.7% were aged 50 to 64 years and 60.3% were aged ≥ 65 years. Incidence rates generally increased with age. 
The most common serotypes in S. pneumoniae-positive CXR+CAP patients were 3 (n = 15), 23F (n = 10), 18C (n = 9), and 9V (n = 6).
Conclusions: CAP due to PCV13 serotypes is a source of morbidity among adults >50 years and may be reduced by greater 
access to pneumococcal vaccines. 
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Introduction 
Pneumonia is a leading cause of death in 
adults worldwide[1, 2]; the incidence of pneumo-
nia and hospitalization for pneumonia increases 
with age [3, 4]. Similarly, the burden of commu-
nity-acquired pneumonia (CAP), often caused by 
Streptococcus pneumoniae [1, 4−7] is greater in 
older adult populations [8]. A review of primary 
articles reporting studies conducted in Europe, 
published from 1990 to 2007, assessing the cli-
nical and economic burden of CAP found that 
incidence and associated mortality were highest 
in those ≥ 65 years of age [9]. In Poland from 2008 
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to 2009, all-cause, inpatient CAP increased with 
age, with rates of 1.5, 4.0, 8.8, and 16.8 per 1000 
adults aged 50 to 64, 65 to 74, 75 to 84, and 85 to 
99 years, respectively [10]; the case fatality rate 
for patients ≥ 50 years with CAP was 18.6% [10]. 
In Polish adults from 2006 to 2009, incidence 
rates of invasive pneumococcal disease (IPD), 
which includes bacteremic CAP, were generally 
low in those ≥ 50 years (from 0.07−1.93 per 1000 
inhabitants). The most common S. pneumoniae 
serotypes were 1, 3, 4, 9V, 9N, 12F, 14, 19F, and 
23F in those ≥ 55 years of age [11]. 
Although S. pneumoniae is a common cause 
of CAP, there are a dearth of epidemiologic data 
for the pneumococcal CAP burden in adults, 
and epidemiologic studies are often hampered 
by inadequate assessment methods. In Poland, 
disease incidence rates for IPD are based on cases 
identified via laboratory-confirmed surveillance 
systems (eg, cultures of blood and other sterile 
fluids). However, factors such as prior treatment 
with antibiotics may limit isolation of viable or-
ganisms, causing underestimation of incidence 
rates [12]. Furthermore, CAP associated with 
nonbacteremic or noninvasive pneumococcal 
disease is not fully captured by these methods, 
and no universal standard exists for the measure 
of noninvasive disease [13]. The commercially 
available BinaxNOW® S. pneumoniae Antigen 
Card (Alere Inc.,Waltham, MA) and the proprie-
tary 13-valent multiplex urine antigen detection 
(UAD; Pfizer Inc, New York, NY) assay provide 
an opportunity to specifically assess the preva-
lence of noninvasive pneumococcal disease by 
allowing for the identification of nonbacteremic 
pneumonia cases through urine testing [14, 15]. 
Although BinaxNOW does not distinguish be-
tween S. pneumoniae serotypes, the UAD assay is 
capable of identifying serotypes specific to 13-va-
lent pneumococcal conjugate vaccine (PCV13). 
Thirteen-valent pneumococcal conjugate vac-
cine was approved in Europe for prevention of 
invasive disease and pneumonia caused by the 
corresponding S. pneumoniae serotypes in adults 
aged ≥ 18 years and in the elderly [16]. PCV13 re-
placed 7-valent PCV (PCV7) due to the emergence 
of nonvaccine serotypes [17]. Recent data from ap-
proximately 85,000 patients from the Community-
-Acquired Pneumonia Immunization Trial in Adults 
(CAPiTA) supported the efficacy of PCV13 in adults 
aged ≥ 65 years, demonstrating efficacy compared 
with placebo against vaccine-type CAP (including 
nonbacteremic CAP) and vaccine-type IPD [18].
Despite reported benefits of PCV13 in adults, 
vaccination is not widespread in Polish adults, 
in whom vaccine-preventable pneumococcal 
disease remains a factor. In adults aged ≥ 55 
years in Poland, 36% to 89% of IPD cases from 
2006 to 2009 were caused by serotypes covered 
by 1 of the currently approved pneumococcal 
vaccines [11]. Despite the availability of PCVs 
in Poland since 2005, no national pneumococcal 
immunization efforts have been undertaken. It 
is now recommended that adults with chronic 
diseases and those >50 years receive PCV13 or 
23-valent pneumococcal polysaccharide vaccine 
(PPSV23) [19]. However, PCV reimbursement 
is limited to children aged 2 months to 5 years 
who are at high risk for IPD or have chronic di-
seases; this factor likely contributes to PCV vac-
cination being largely confined to this subgroup 
[20]. Moreover, uptake of PPSV23 is historically 
low, with only 0.1% of Polish adults aged > 65 
years receiving ≥ 1 PPSV23 dose from 2004 to 
2006 [21]. Improved understanding of serotypes 
causing bacteremic and nonbacteremic CAP in 
Polish adults is necessary to guide vaccination 
policies. Thus, the primary objective of this 
study was to estimate prospective incidence of 
CAP, chest x-ray–confirmed CAP (CXR+CAP), 
S pneumoniae-positive CAP, and S pneumoniae- 
-positive CXR+CAP among adults aged ≥ 50 years 
in Chrzanów County, Poland, from 2010 to 2012. 
Secondary objectives were to describe S. pneumo-
niae serotype distribution and CAP fatality rates 
in this population.
Material and methods
Study design and enrollment
This active, prospective, population-ba-
sed surveillance study of CAP in adults aged 
≥ 50 years (conducted from January 14, 2010, to 
January 13, 2012) included all healthcare faci-
lities in Chrzanów County, Małpolskie, Poland, 
that provided ambulatory and inpatient care 
(1 hospital and 30 freestanding public and private 
clinics). Eligible patients included resident adults 
aged ≥ 50 years with suspicion of CAP who were 
seeking healthcare. 
The criteria used to select the surveillance 
area included a well-defined population of eligible 
patients; definable and limited number of study 
hospitals and outpatient clinics; high-quality 
in-hospital clinical microbiology testing; low rates 
(< 5% per year) of migration; ability to diagnose and 
treat adults with severe disease associated with 
CAP; feasibility of obtaining information about 
healthcare use and healthcare system description 
(structure, referral, coordination/management); 
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and ability of the investigator to implement and 
sustain CAP population-based surveillance during 
the course of a 2-year study period. 
Community-acquired pneumonia was defined 
as infection of the alveoli, distal airways, and 
lung interstitium occurring outside the hospital. 
Patients were suspected of having CAP if they had 
≥ 1 of the following clinical signs or symptoms of 
respiratory illness: fever (temperature ≥ 38.0°C) 
or hypothermia (temperature ≤ 35.5°C) within 24 
hours of enrollment, chills or rigors, pleuritic chest 
pain, cough, sputum production, dyspnea, tachyp-
nea, malaise, or abnormal auscultatory findings 
suggestive of pneumonia. Patients were excluded if 
they were transferred to a participating healthcare 
facility after already being hospitalized for ≥ 48 
hours or had developed signs and symptoms of 
pneumonia after being hospitalized for ≥ 48 hours. 
Patients participated directly in the study 
for 1 day. Following enrollment, chest x-ray was 
performed; clinical specimens were collected; and 
patients were interviewed to obtain demographic 
and family information, medical history, and pre-
vious antibiotic use. A final diagnosis and vital 
status were confirmed ≤ 10 days postenrollment; 
for patients hospitalized for ≥ 10 days, vital status 
was assessed ≤ 120 days postenrollment. The stu-
dy was undertaken in accordance with the Decla-
ration of Helsinki and International Conference 
on Harmonisation Guidelines for Good Clinical 
Practice and Good Epidemiological Practice. All 
enrolled patients underwent a standardized in-
formed consent process. 
Study populations 
The overall CAP cohort included all patients 
with a final diagnosis of pneumonia. The CXR+-
CAP cohort included all patients with clinical 
pneumonia whose chest radiograph result was 
consistent with pneumonia as read by a radio-
logist. The S. pneumoniae-positive CAP cohort 
included all patients with a positive result for 
S. pneumoniae detected from culture (blood or 
acceptable-quality respiratory specimen [eg, spu-
tum, bronchial wash]) or urine test (BinaxNOW S. 
pneumoniae Antigen Card [14] or a 13-valent mul-
tiplex UAD assay [15]). The S. pneumoniae-positive 
CXR+CAP cohort included all patients with 
clinical pneumonia who were S. pneumoniae- 
-positive and whose chest radiograph result was 
consistent with pneumonia.
Procedures 
Digitalized chest x-rays were performed and 
read by the principal investigator and 2 central 
readers at the inpatient location. Nasopharyn-
geal swabs and blood for bacteriologic culture 
were collected upon enrollment. Sputum was 
collected if clinically indicated. Other respira-
tory specimens (eg, tracheal aspirates, bronchial 
washing, pleural fluid) were collected for culture 
and Gram stain according to local standard of 
care. All respiratory and blood samples unde-
rwent bacterial culture at the local laboratory 
according to standard methodology for identifi-
cation of S. pneumoniae and other pathogens. All 
S. pneumoniae isolates identified by the local la-
boratory were sent on transport media to a central 
laboratory for confirmation of identification and 
serotyping by the Quellung reaction.
Urine samples were tested using Pfizer’s 
proprietary serotype-specific UAD assay, which 
detects S pneumonia serotypes 1, 3, 4, 5, 6A/C, 6B, 
7F/A, 9V/A, 14, 18C/A/B/F, 19A, 19F, and 23F [15]. 
Urine samples were also tested using the commer-
cially available S. pneumoniae BinaxNOW assay. 
Statistical analysis 
Statistical analyses were descriptive. In-
cidence rate was defined as the number of new 
cases of CAP in the population aged ≥ 50 years in 
the surveillance area divided by the total at-risk 
population aged ≥ 50 years in the surveillance 
area. For the 2-year study period, aggregated 
annualized incidence rates were reported per 
1000 residents per year with 95% CI based on 
the Poisson distribution. Case fatality rate for 
the 2 years was expressed as the percentage of 
cases resulting in death during postenrollment 
follow-up among all persons diagnosed with CAP.
Results
Study populations
In 2010 and 2011, the estimated population 
of Chrzanów County, Poland, was 127,645 and 
127,540 residents, respectively, and the at-risk po-
pulation comprised 46,134 and 46,962 people, re-
spectively, aged ≥ 50 years. In total, 5055 patients 
were enrolled in the present study; however, 
6 subjects did not have respiratory illness which 
resulted in a total of 5049 patients, of whom 1195 
(23.7%) were diagnosed with CAP (Table 1) and 
1166 (23.4%) had CXR+CAP. S. pneumoniae was 
detected in 144 (12.1%) and 131 (11.2%) patients 
from the CAP and CXR+CAP cohorts, respectively. 
The remaining 3854 (76.3%) patients were found to 
have other non-CAP respiratory illnesses, the majo-
rity of which were lower respiratory tract infections 
(62.3%; 3146/5049 patients). The majority of CAP 
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 Table 1. Patient demographics and clinical characteristics 
Variable Overall cohort*
n = 5055
CAP
n = 1195
S pneumoniae-positive CAP
n = 144
Age
 Mean ± SD, y 65.2 ± 10 68.1 ± 10.5 68.3 ± 11.4
 Years, n (%)
   50–64 2653 (52.5) 481 (40.3) 58 (40.3)
   65–69 645 (12.8) 161 (13.5) 21 (14.6)
   70–79 1263 (25.0) 355 (29.7) 36 (25.0)
   ≥ 80 494 (9.8) 198 (16.6) 29 (20.1)
 Sex 
  Female 2911 (57.6) 619 (51.8) 69 (47.9)
  Male 2144 (42.4) 576 (48.2) 75 (52.1)
 Previous enrollment in study 
  Yes 334 (6.6) 120 (10.0) 18 (12.5)
 Hospitalized for pneumonia in the past 5 years 
  No 4680 (92.6) 1058 (88.5) 116 (80.6)
  Yes 364 (7.2) 137 (11.5) 28 (19.4)
  Unknown 11 (0.2) 0 0
Previous PCV†
 No NA 1191 (99.7) 143 (99.3)
 Yes NA 0 0
 Unknown NA 4 (0.3) 1 (0.7)
Previous PPV†
 No NA 1195 (100) 144 (100)
 Yes NA 0 0
 Unknown NA 0 0
Previous influenza vaccine†,‡
 No NA 1080 (90.4) 131 (91.0)
 Yes NA 112 (9.4) 12 (8.3)
 Unknown NA 3 (0.3) 1 (0.7)
Smoking history
 Current smoker NA 235 (19.7) 44 (30.6)
  Former smoker NA 513 (42.9) 59 (41.0)
  Never smoked NA 447 (37.4) 41 (28.5)
CAP — community-acquired pneumonia; NA — not applicable; PCV — pneumococcal conjugate vaccine; PPV — pneumococcal polysaccharide vaccine
*Annualized data from both study years
†Vaccination data were self-reported
‡Vaccination within the past year
patients were current (19.7%) or former (42.9%) 
smokers, only 9.4% had received an influenza vac-
cine within the past year, and none had previously 
received a pneumococcal vaccine. 
Of patients diagnosed with CAP, 40.3% were 
aged 50 to 64 years and 59.8% were aged ≥ 65 
years (Table 1). Almost 40% of CAP patients were 
hospitalized, and the remaining patients required 
only an emergency department stay or outpatient 
care. For hospitalized patients, the mean ± SD 
length of stay was 10.9 ± 7.1 days. Nearly all cases 
of CAP (97.6%) were radiographically confirmed 
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Table 2. Incidence rates of pneumonia
Diagnosis Number of cases* Number
in at-risk
population
Incidence rate per
1000 population
(95% CI)
 CAP 1195 93,096 12.8 (12.1–13.6)
Age groups, y
  50–64 481 55,780 8.6 (7.9–9.4)
  ≥ 65 714 37,316 19.13 (17.7–20.6)
  65–69 161 9907 16.3 (13.8–19.0)
  70–79 355 19,082 18.6 (16.7–20.6)
  ≥ 80 198 8327 23.8 (20.6–27.3)
CXR+CAP 1166 93,096 12.5 (11.8–13.3)
Age groups, y
  50–64 469 55,780 8.4 (7.7–9.2)
  ≥ 65 697 37,316 18.7 (17.3–20.1)
  65–69 156 9907 15.8 (13.4–18.4)
  70–79 346 19,082 18.1 (16.3–20.2)
  ≥ 80 195 8327 23.4 (20.3–27.0)
S. pneumoniae-positive CAP 144 93,096 1.6 (1.3–1.8)
Age groups, y
  50–64 58 55,780 1.0 (0.8–1.3)
  ≥ 65 86 37,316 2.3 (1.8–2.9)
  65–69 21 9907 2.1 (1.3–3.2)
  70–79 36 19,082 1.9 (1.3–2.6)
  ≥ 80 29 8327 3.5 (2.3–5.0)
S. pneumoniae-positive CXR+CAP 131 93,096 1.4 (1.2–1.7)
Age groups, y
  50–64 52 55,780 0.9 (0.7–1.2)
  ≥ 65 79 37,316 2.1 (1.7–2.6)
  65–69 17 9907 1.7 (1.0–2.8)
  70–79 33 19,082 1.7 (1.2–2.4)
  ≥ 80 29 8327 3.5 (2.3–5.0)
CAP — community-acquired pneumonia; CXR+CAP — chest x-ray−confirmed CAP
*Annualized data from both study years
(CXR+CAP; Table 2); 40.3% and 59.7% of CAP pa-
tients and 40.2% and 59.8% of CXR+CAP patients 
were aged 50 to 64 and ≥ 65 years, respectively. 
More than 50% of patients with S. pneumoniae
-positive CAP were hospitalized, and the length 
of stay was 10.6 ± 5.6 days. More than 90% of 
S. pneumoniae-positive CAP patients (131/144 
patients) were also CXR positive (Table 2). 
A total of 11.2% (131/ 1166) patients with CXR+-
CAP were S. pneumoniae positive, 62.6% of 
whom were former or current smokers. More 
than half of patients with S. pneumoniae-positive 
CXR+CAP were hospitalized and the length of 
stay was 10.4 ± 5.4 days. 
Incidence rates
The annualized incidence rate of CAP and 
CXR+CAP in at-risk adults was 12.8 and 12.5 per 
1000 residents, respectively, and rose to 19.1 and 
18.7 per 1000 residents in adults aged ≥ 65 years 
(Table 2). The incidence of S. pneumoniae-positive 
CAP and S. pneumoniae-positive CXR+CAP in 
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adults aged < 65 years was 1.6 and 1.4 per 1,000 
residents, respectively, and incidence increased 
to 2.3 and 2.1 per 1000 residents in adults aged 
≥ 65 years (Table 2). Overall, the incidence of 
CAP, CXR+CAP, S. pneumoniae-positive CAP, and 
S. pneumoniae-positive CXR+CAP increased 
with age. Results across all cohorts were similar 
in both study years. 
Case fatality
Nineteen (1.6%) patients with CAP died in 
the follow-up period. Deaths were distributed 
across age groups (5 were aged 50–64 years; 
14 were aged ≥ 65 years). Of these 19 patients, 
18 (1.5%) had CXR+CAP; S. pneumoniae was 
identified in 1 patient. 
Streptococcus pneumoniae culture from 
blood and sputum samples 
All 1195 patients with CAP had blood cul-
tures; none grew S. pneumoniae. Among CAP 
patients, 21.4% reported antibiotic use in the 
week before enrollment; 7 had S. pneumoniae 
confirmed by the central laboratory from sputum 
samples and 8 from bronchial wash/broncho-
alveolar lavage samples. All but 1 patient with 
CAP had a nasopharyngeal swab, and 7 patients 
(2.4%) had swabs that grew S. pneumoniae. 
Urine analyses for Streptococcus 
pneumoniae
A UAD and/or BinaxNOW assay was perfor-
med on urine samples obtained from 98.3% of 
enrolled patients (4971 and 4970, respectively). 
A total of 107 patients had an S. pneumoniae- 
-positive UAD result, and 69 of these patients had 
CAP. Of the 242 patients with an S. pneumoniae- 
-positive BinaxNOW result, 97 had CAP. Few 
patients (32 of 1195 with CAP [2.7%]) had both 
a positive UAD and BinaxNOW assay result. 
Three patients were positive by sputum and 
BinaxNOW and/or UAD, and 3 were positive by 
lavage and BinaxNOW and/or UAD.
Streptococcus pneumoniae serotypes 
Of the 144 patients with S. pneumoniae-
-positive CAP, 76 had PCV13 serotypes, 1 had 
a non-PCV13 serotype (serotype 9N), 1 was not 
serotyped, and 66 were positive by BinaxNOW 
only. All but 1 of the 68 serotypes identified in 
patients with S. pneumoniae-positive CXR+CAP 
were PCV13 serotypes; the only non-PCV13 
serotype was 9N (Table 3). The most common 
serotypes identified were 3 (n = 15), 23F (n = 10), 
18C (n = 9), and 9V (n = 6; Table 3). Serotypes 
identified included PCV7 serotypes 14 and 23F 
(1 patient each); additional PCV13 serotype 1 
(2 patients); and non-PCV13 serotypes 9N, 11A, 
and 23B (1 patient each).
Discussion
A burden of CAP and S. pneumoniae-positive 
CAP existed in older adults in Chrzanów County, 
Poland, during study years 1 and 2, and for the 
annualized results. Typical for most of Poland, 
pneumococcal vaccination in Chrzanów is rare 
among adults [21] and limited to young children 
with high-risk conditions. CAP incidence in pa-
tients aged ≥ 65 years (19.13 per 1000 residents) 
was similar to that found in a retrospective 
assessment of CAP burden in Kielce, Poland 
(19.4 per 1000 residents) before the introduction 
of a municipal PCV7 vaccination program in 
young children [3]. The annual incidence rate 
of CXR+CAP in rural Crete, Greece was 2.4 per 
1000 residents, lower than that observed in the 
current study (12.5 per 1000), potentially due to 
differences in disease incidence or variations in 
study design/data collection [22]. 
Most serotypes in S. pneumoniae-positive 
CAP patients were identified using the UAD assay 
and, thus, included only PCV13 serotypes. The 
most frequently identified serotypes were 3, 23F, 
18C, and 9V. Only 1 non-PCV13 serotype (9N) 
was identified. The lack of non-PCV13 serotypes 
is a result of an unexpectedly low culture yield 
as opposed to any change in the prevalence of 
specific serotypes. In a previous Polish study 
conducted from 2006 to 2009 among adults aged 
≥ 55 years with IPD, serotypes 3 and 23F were 
among the most common, whereas serotypes 18C 
and 6A were less common [11]. These differences 
may reflect differing etiologies of noninvasive 
versus invasive disease or the relative sensiti-
vities of the different bacterial identification 
methods. For example, validation studies for the 
UAD assay demonstrated 97% sensitivity for the 
13 PCV13 serotypes compared with traditional 
blood culture [15].
Earlier studies demonstrated the utility 
of an assay similar to the UAD assay in the 
identification of serotypes associated with 
noninvasive CAP [23, 24]. Differences in the 
prevalence of serotypes identified in urine 
samples compared with those identified in 
cases of bacteremic disease in 2 hospitals in 
the United Kingdom have been reported [23]. 
The most prevalent serotype found in urine 
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Table 3.  S pneumoniae serotypes among subjects with CXR+CAP, and S. pneumonia-positive non-CXR+CAP and other 
respiratory infection* 
S. pneumonia-positive
Cases (%)
Serotype† CXR+CAP
(n = 131)
serotyped n = 67
non–CXR+CAP
(n = 13)
serotyped n = 10
Other respiratory  
infection‡ (n = 177)
serotyped n = 38
Total
(n = 321)
serotyped n = 115 
 PCV7 serotypes
4 5 (7.5) 0 1 (2.6) 6 (5.2)
6B 5 (7.5) 3 (30) 4 (10.5) 12 (10.4)
9V 6 (9.0) 0 2 (5.3) 8 (7.0)
14 5 (7.5) 0 12 (31.6) 17 (14.8)
18C 9 (13.4) 1 (10) 7 (18.4) 17 (14.8)
19F 3 (4.5) 1 (10) 1 (2.6) 5 (4.3)
23F 10 (14.9) 1 (10) 5 (13.2) 16 (13.9)
All PCV7 serotypes 
combined 
43 (64.2) 6 (60) 32 (84.2) 81 (70.4)
PCV13 serotypes
 6 additional serotypes in PCV13
1 1 (1.5) 3 (30) 1 (2.6) 5 (4.3)
3 15 (22.4) 0 0 15 (13.0)
5 1 (1.5) 1 (10) 4 (10.5) 6 (5.2)
6A 4 (6.0) 0 0 4 (3.5)
7F 1 (1.5) 0 1 (2.6) 2 (1.7)
19A 2 (3.0) 0 1 (2.6) 3 (2.6)
6 additional PCV13 se-
rotypes combined 
23 (34.3)§ 4 (40) 7 (18.4) 34 (29.6)
All PCV13 serotypes 
combined 
66 (98.5)§ 10 (100) 38 (100) 114 (99.1)§
Non-PCV13 serotypes
9N 1 (1.5) 0 0 1 (.9)
BinaxNOW-only  
positive 
64 (NA) 2 (NA) 139 (NA) 205 (NA)
CAP — community-acquired pneumonia; CXR — chest x-ray; NA — not applicable; PCV7 — 7-valent pneumococcal conjugate vaccine; PCV13 — 13-valent pneumo-
coccal conjugate vaccine; UAD — urine antigen detection
*Annualized data from both study years
†Results based on blood, respiratory, and urine samples. Isolates from respiratory specimens were serotyped using the Quellung reaction. Urine samples were serotyped 
using the UAD assay
‡Includes those with other nonpneumonia respiratory diseases
§One subject had more than 1 unique serotype result: 6A and 19A
samples collected in support of that study was 
serotype 14. This serotype was not represented 
within the bacteremic group, suggesting that its 
prevalence may have been underestimated [23]. 
Similar results using the same UAD as the cur-
rent study have been reported [24]. These data 
suggest that serotype distribution measured in 
bacteremic pneumonia may not represent the 
serotypes causing noninvasive pneumonia in 
those same groups.
The current analysis has inherent strengths 
and limitations. Clear strengths lie within its de-
sign as a prospective, population-based study — 
the gold standard in burden of disease analysis. 
Moreover, the surveillance method provided 
a comprehensive assessment of disease among 
older adults in Chrzanów County, Poland, by 
systematically enrolling all patients with suspec-
ted CAP from all primary care clinics and the 
1 hospital in the county. Based on the surveil-
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lance estimate, the overall proportion of eligible 
subjects enrolled was 92% (95% CI, 91.3–92.7); 
the number of patients aged >50 years registered 
for primary care in the county (n = 45,356 as 
of January 1, 2010) was 98.3% of the estimated 
county population within these age groups (n = 
46,134; population as of December 31, 2009). This 
congruence suggests that almost all adult inhabi-
tants of Chrzanów County received their medical 
care within the county, although this was not 
confirmed with a survey. Finally, S. pneumoniae 
infection and associated serotypes were identified 
using the UAD assay, allowing for the detection 
of nonbacteremic pneumonia cases using urine 
testing and providing more specific information 
on S. pneumoniae serotypes associated with no-
ninvasive disease.
Study limitations include the fact that it was 
conducted in only 1 county in Poland; consequ-
ently, results may not be widely generalizable. 
However, a prior hospital-based study using elec-
tronic administrative data comparing Chrzanów 
and Inowrocław County hospitals from 2006 to 
2008 found a higher incidence of hospitalization 
for pneumonia in Inowrocław County in most age 
groups, including older adults [25]. Among the 
1077 eligible hospitalized patients, 26.5% were 
not enrolled, primarily due to mental incapacity 
to provide informed consent. Therefore, CAP 
incidence may be underestimated. Further com-
plicating estimates of S. pneumoniae incidence, 
almost 25% of patients with clinical pneumonia 
self-reported antibiotic treatment in the week 
before enrollment. This may have reduced viable 
bacteria yield in blood and respiratory speci-
mens. Although lack of positive blood cultures 
was unexpected, assessment with UAD and 
BinaxNOW assays permitted identification of S. 
pneumoniae infections not identified by blood 
culture. 
Conclusions
Despite limited epidemiologic data on 
pneumococcal CAP in Poland, trends of po-
pulation aging and increased morbidity in the 
elderly [3, 4] in association with the cost of 
treatment, support the need to prevent CAP in 
Polish adults with an effective vaccine. Results of 
this prospective, population-based study suggest 
that pneumonia burden in Poland is substantial 
and is consistent with previous analyses [8]. 
Continued surveillance of noninvasive CAP is 
required to better understand which serotypes 
are responsible for causing disease in this setting. 
Additionally, greater rigor in culture methods 
might affect yield in future studies. Despite these 
challenges, CAP due to PCV13 serotypes clearly 
remains a source of morbidity among adults in 
Chrzanów County. PCV13 vaccination of older 
adults, along with broader vaccination of infants, 
has the potential to reduce pneumococcal disease 
incidence in Poland. 
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